Telix Pharmaceuticals Ltd (TLX) Form 6-K — Oct 20, 2026
Telix Pharmaceuticals reported Q3 2026 group revenue of US$245 million, up 19% year-over-year, with Precision Medicine revenue of US$201 million up 30%, driven by strong demand for its PSMA-PET imaging agents Gozellix and Illuccix. The company reaffirmed FY 2026 revenue and other income guidance in excess of US$1 billion and revised its R&D expenditure guidance to US$240-260 million.
Key figures
- Revenue
- 245000000
- Guidance
- FY 2026 revenue and other income expected to exceed US$1 billion; revenue tracking toward upper end of US$950M-US$970M guidance plus US$40M other income; R&D expenditure guidance revised to US$240M-US$260M (previously US$230M-US$270M)
- Revenue Yoy
- 19%
- Tms revenue
- US$44M (-6% YoY)
- Bipass enrollment
- 350 patients
- Q2 2026 group revenue
- US$247M
- Optimal psma enrollment
- 120 patients
- Itm merger share component
- approximately US$1.25 billion in Telix shares as ADRs
- Precision medicine revenue
- US$201M (+30% YoY)
- Itm merger upfront consideration
- US$1.65 billion
- Itm merger contingent consideration
- up to US$700 million
- Quantm irradiation systems contracts
- 50
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.